Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study
Authors:
Open Access
- 24 September 2025
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 84, 104583
Abstract
No abstract availableKeywords
Funding Information
- Netherlands Organisation for Health Research and Development
This publication has 32 references indexed in Scilit:
- Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutionsBreast Cancer Research and Treatment, 2022
- Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018Breast Cancer Research and Treatment, 2022
- Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE RegistryBreast Cancer Research and Treatment, 2021
- Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?Breast Cancer Research and Treatment, 2019
- Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experienceBreast Cancer Research and Treatment, 2019
- Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysisBreast Cancer Research and Treatment, 2017
- Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancerBreast Cancer Research and Treatment, 2016
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancerBreast Cancer Research and Treatment, 2014
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenBreast Cancer Research and Treatment, 2005